2型糖尿病患者体重变化与心血管疾病及死亡风险:ADVANCE研究
与体重稳定者相比,2年内体重下降超过10%者主要大血管事件、心血管死亡和全因死亡风险显著增加,但微血管事件风险无显著变化。
要点
- 2年内体重下降>10%与主要大血管事件风险升高相关(HR 1.75)。
- 体重下降>10%者心血管死亡和全因死亡风险分别升高至2.76倍和2.79倍。
- 无充分生活方式干预的体重下降应警惕潜在健康问题。
核心结论
- 在无显著生活方式改变的情况下,2型糖尿病患者体重下降可能是健康状况不佳的警示信号,需进一步评估。
研究设计与样本
- ADVANCE试验为国际多中心2×2析因设计,比较强化降糖和降压治疗。
- 采用Cox回归分析,随访自第2年起,调整干预组、人口学、心血管危险因素及降糖药物使用。
主要发现
- 2年时,4.3%患者体重下降>10%,18.4%下降4%-10%,5.3%增加>10%。
- 与体重稳定(±<4%)相比,体重下降>10%者主要大血管事件HR 1.75(95%CI 1.26-2.44)。
- 体重下降>10%者心血管死亡HR 2.76(95%CI 1.87-4.09),全因死亡HR 2.79(95%CI 2.10-3.71)。
- 体重下降>10%与主要微血管事件无显著关联(HR 0.91;95%CI 0.61-1.36)。
- 基线BMI、年龄或降糖药物类型未见效应修饰。
临床怎么用
- 对2型糖尿病患者,若出现非刻意体重下降>10%,应警惕并进一步排查潜在疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes. Unintentional weight loss is associated with increased risk of all-cause mortality, but few studies have examined its association with cardiovascular outcomes in patients with diabetes. OBJECTIVE: To evaluate 2-year weight change and subsequent risk of cardiovascular events and mortality in established type 2 diabetes. DESIGN AND SETTING: The Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation was an international, multisite 2×2 factorial trial of intensive glucose control and blood pressure control. We examined 5 categories of 2-year weight change: >10% loss, 4% to 10% loss, stable (±<4%), 4% to 10% gain, and >10% gain. We used Cox regression with follow-up time starting at 2 years, adjusting for intervention arm, demographics, cardiovascular risk factors, and diabetes medication use from the 2-year visit. RESULTS: Among 10 081 participants with valid weight measurements, average age was 66 years. By the 2-year examination, 4.3% had >10% weight loss, 18.4% had 4% to 10% weight loss, and 5.3% had >10% weight gain. Over the following 3 years of the trial, >10% weight loss was strongly associated with major macrovascular events (hazard ratio [HR], 1.75; 95% confidence interval [CI], 1.26-2.44), cardiovascular mortality (HR, 2.76; 95% CI, 1.87-4.09), all-cause mortality (HR, 2.79; 95% CI, 2.10-3.71), but not major microvascular events (HR, 0.91; 95% CI, 0.61-1.36), compared with stable weight. There was no evidence of effect modification by baseline body mass index, age, or type of diabetes medication. CONCLUSIONS: In the absence of substantial lifestyle changes, weight loss may be a warning sign of poor health meriting further workup in patients with type 2 diabetes.
引用
- Lee AK, Woodward M, Wang D, et al. The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. J Clin Endocrinol Metab. 2020. PMID: 31588504. doi:10.1210/clinem/dgz045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。